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Prion infections cause lethal neurodegeneration. This process requires the cellular prion 
protein1 PrPC which contains a globular domain (GD) hinged to a long N-proximal flexible 
tail (FT)2. Here we describe rapid neurotoxicity in mice and cerebellar organotypic cultured 
slices (COCS) exposed to ligands targeting the α1 and α3 helices of the GD. Ligands 
included seven distinct monoclonal antibodies3, monovalent F(ab)1 fragments, and 
recombinant single-chain miniantibodies derived therefrom. Similarly to prion infections4-6, 
toxicity of GD ligands required neuronal PrPC, was exacerbated by PrPC overexpression, 
was associated with calpain activation, and was antagonized by calpain inhibitors. 
Neurodegeneration was accompanied by a burst of reactive oxygen species, and was 
suppressed by antioxidants. Furthermore, genetic ablation of the superoxide-producing 
enzyme NOX2 protected mice from GD ligands. We also found that neurotoxicity was 
prevented by deletions of the octapeptide repeats within the FT. These deletions did not 
appreciably compromise GD antibody binding, suggesting that the FT is required to 
transmit toxic signals that emanate from the GD and trigger oxidative stress and calpain 
activation. Supporting	this	view,	various	octapeptide	ligands	were	not	only	innocuous	
to	 both	 COCS	 and	 mice,	 but	 also	 prevented	 the	 toxicity	 of	 GD	 ligands	 while	 not	
interfering	with	their	binding. We conclude that PrPC consists of two functionally distinct 
modules, with the GD and the FT exerting regulatory and executive functions, respectively. 
Octapeptide ligands also prolonged the life of mice expressing the toxic PrPC mutant7, 
PrPΔ94-134, indicating that the FT mediates toxicity in two distinct PrPC-related conditions. 
FT-mediated toxicity may conceivably play a role in further prion pathologies, such as 
familial Creutzfeldt-Jakob disease in humans bearing supernumerary octapeptides.	
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The infectious prion PrPSc, which causes transmissible spongiform encephalopathies, is a 
pathological conformer of PrPC, a glycosylphosphatidyl-inositol (GPI) linked cell-surface protein 
encoded by the Prnp locus8. Only PrPC-expressing cells are damaged by prion infections1, 
suggesting that neurotoxicity is triggered by PrPC-PrPSc interactions on cell membranes. In an 
effort to model such interactions, we exposed cerebellar organotypic cultured slices (COCS)4,9 to 
a panel of anti-PrP antibodies directed against well-defined PrPC epitopes3. Supplementary Figure 
1 summarizes our main findings, and Supplementary Table 1 lists all abbreviations.  
PrPC-overexpressing COCS (derived from tga20 mice that are hypersensitive to prion 
diseases5) were treated with 5 antibodies against the flexible tail of PrPC (FT, residues 23-123) 
(ref. 10) and with 12 antibodies against the globular domain of PrPC (GD, residues 124-230; 
Supplementary Table 2; Fig. 1a). Seven of the antibodies targeting the GD induced dramatic loss 
of cerebellar granule cells (CGC) at 67 nM and one was toxic at 333 nM, whereas four were 
innocuous (Fig. 1b). None of three high-affinity antibodies to the octapeptide repeats (OR, 
residues 50-90 embedded within the FT) were neurotoxic (Fig. 1b). Antibodies POM3 and D13, 
which bind the “charged cluster-2”11 (CC2, residues 95-110), were innocuous at 67 nM but 
neurotoxic at 200 nM (Fig. 1b). None of the tested antibodies were toxic to Prnpo/o COCS 
(Supplementary Fig. 2a). The identity of the targeted epitopes appeared to be a better predictor of 
PrPC antibody toxicity than their affinity to PrPC, suggesting that neurotoxicity resulted from the 
interaction of antibodies with specific PrPC domains (Supplementary Table 2).  
The mechanisms of neurotoxicity were further explored using POM1, a highly toxic 
antibody targeting the GD. Wild-type (wt) and tga20 COCS lost most granule cells (CGC) within 
28 and 14 days post-exposure (dpe) to POM1, respectively (Fig. 2a-c). Controls included POM1-
treated Prnpo/o COCS12, tga20 COCS treated with pooled mouse immunoglobulins (IgG), and 
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tga20 COCS treated with POM1 preincubated with full length recombinant mouse PrP 
(rmPrP23-230). All of these controls were unaffected (Fig. 2d), indicating that POM1 toxicity was 
PrPC-dependent. Propidium iodide (PI) staining, a marker of cell death, revealed that CGC 
membrane integrity was compromised before overt neuronal loss in POM1-treated tga20 COCS. 
The prevalence of PI+ cells peaked at 3-5 days and decreased thereafter, suggesting removal of 
dead cells (Fig. 2e, Supplementary Fig. 3). Therefore POM1-mediated neurotoxicity was 
dependent on Prnp gene-dosage as well as duration and dosage of the antibody treatment. 
Similarly to neurotoxicity in prion infections6, neuronal PrPC expression was necessary and 
sufficient for POM1 toxicity (Supplementary Fig. 4a-c), suggesting that its effects were cell-
autonomous to neurons. Finally, treatment of COCS with an anti-NOGO receptor antibody was 
innocuous, indicating that toxicity was not a generic consequence of binding to GPI-linked 
receptors (Supplementary Fig. 4d).  
It was previously reported that antibody-mediated crosslinking of PrPC at the cell surface 
leads to neurotoxicity11. However, both monovalent and divalent POM1, POM17 and POM19 
derivatives (F(ab)1 fragments, F(ab)2 fragments, and recombinant single-chain (scFv) 
miniantibodies) induced neurotoxicity in tga20 COCS but not in Prnpo/o COCS (Fig. 2f-g and 
Supplementary Figs. 5 and 2b). Hence neurotoxicity was rapidly induced by structurally diverse 
GD ligands, and did not require antibody effector functions mediated by Fc receptors (Fig. 2f-g) 
or complement (Supplementary Fig. 6).  
Neurotoxicity may result from conformational changes imposed onto PrPC by POM1. We 
therefore solved the crystal structure of the protein complex containing POM1 F(ab)1 bound to 
recombinant mouse PrP (residues 120-230, rmPrP120-230; Supplementary Fig. 7; Supplementary 
Tables 2 and 3). The POM1 epitope on rmPrP120-230 was discontinuous and included the C-
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terminal part of the β1-α1 loop, the N-terminal part of helix α1, as well as a segment of helix α3. 
The surface area of the interface was ca. 580 Å2, and involved primarily the POM1 heavy chain 
(Supplementary Movie 1 and Supplementary Fig. 7). Comparisons with published 
structures2,10,13,14 indicate that F(ab)1POM1 binding did not cause conformational distortions in 
the GD. We also studied the binding interface of scFvPOM1 complexed with full-length 
recombinant mouse PrP (residues 23-230, rmPrP23-230) by solution nuclear magnetic resonance 
(NMR) spectroscopy. Overlays of the NMR spectra of rmPrP23-230 with those of the 
scFvPOM1:rmPrP23-230 complex did not reveal appreciable perturbations of the FT (Supplementary 
Fig. 8), whereas PrPC residues in contact with scFvPOM1 in the GD displayed chemical shift 
changes as expected from the crystal structure. Moreover, we found subtle perturbations in the 
chemical shifts in the β1/β2 regions that were not present in the crystal structure (Supplementary 
Fig. 8).  
To investigate whether the FT contributes to the neurotoxicity of GD ligands, we 
administered POM1 to COCS expressing either PrPΔ32-93 (lacking most of the FT) or PrPΔ94-110 
(lacking the CC2)15,16 (Supplementary 9a). Whilst PrPΔ94-110 COCS experienced POM1-
dependent neurodegeneration, COCS overexpressing PrPΔ32-93 were resistant to all tested 
neurotoxic antibodies, POM1, POM4, POM8, and POM19 (Fig. 3a, Supplementary Figs. 4b and 
9b,c). The affinities of POM1 F(ab)1 fragments for N-terminally truncated prion protein 
(PrP90-230) and full-length recombinant PrP23-230 were similar (2.9 and 2.5 nM, respectively; 
Supplementary Table 2), confirming that the resistance of PrPΔ32-93 COCS to POM1 effect was 
not due to any steric changes compromising the POM1 binding site.  
These results suggested that the FT is required for GD ligands-mediated toxicity. If so, 
engaging FT with antibodies might prevent the toxicity of GD antibodies. Indeed, preincubation 
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of tga20 COCS with OR antibodies (POM2 or POM11), or with scFv derivatives thereof, blocked 
POM1 toxicity (Fig. 3b-c). Interestingly, low concentrations of POM3 and D13 also blocked 
POM1 toxicity, although these antibodies were intrinsically toxic at higher concentrations (Fig. 
3b). Hence CC2 binders acted similarly to pharmacological “partial antagonists”, triggering 
opposite effects depending on the presence or absence of additional ligands. Crucially, neither 
POM2 nor POM3 sterically hinder POM1 binding3,4 and the non-toxic GD antibody POM5, 
which did not compete for the POM1 epitope3 (Supplementary Fig. 9d) did not rescue 
neurotoxicity (Supplementary Fig. 9e). We conclude that the domain executing toxicity resides 
within the FT.  
Although we suspected that POM1 treatment would result in apoptosis, electron 
micrographs of POM1-treated COCS revealed cell death with morphology distinct from typical 
apoptosis (Supplementary Fig. 10). Furthermore, POM1 did not induce caspase activity (Fig. 3e), 
and the caspase antagonist zVAD conferred no neuroprotection against POM1 (Fig. 3d). Instead, 
proteolysis of the calpain substrates, α-fodrin17 and calpain activity was significantly raised after 
scFvPOM1 and POM1 treatment (Fig. 3e, f), and calpain inhibition prevented POM1-mediated 
toxicity (Fig. 3d). None of the compounds used in the above experiments affected the viability of 
IgG-treated COCS (Supplementary Fig. 11a). Hence POM1 neurotoxicity results in calpain-
dependent cell death, similarly to prion-infected COCS4. 
Oxidative stress is a common promoter of neurodegeneration18, raising the question of its 
possible involvement in the toxicity of GD ligands. Indeed, the reactive oxygen species (ROS) 
scavengers, ascorbate (0.1-2.5 mM) and N-acetyl cysteine, conferred neuroprotection against 
POM1-mediated toxicity (Fig. 3d, Supplementary Fig. 11b, c). Long-term incubation of POM1 
with ascorbate did not reduce the binding of POM1 to rmPrP23-230, ruling out that antioxidants 
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affected antibody stability (Supplementary Fig. 11c). The cell-impermeable isoascorbate was also 
protective, suggesting that the relevant ROS were extracellular (Fig. 3d, Supplementary 11a). 
Moreover, inhibition of nitric oxide production showed no protective effect, whereas the 
superoxide dismutase mimetic MnTBAP abolished POM1 neurotoxicity (Fig. 3d and 
Supplementary Fig. 11a), pointing to superoxide rather than nitric oxide as the critical ROS 
species. NADPH oxidases (NOX) are an important source of extracellular superoxide19, and 
indeed scFvPOM1 treatment induced a superoxide spike in COCS that was suppressed by the 
NADPH oxidase (NOX) inhibitor, diphenyleneiodonium chloride (DPI; Fig. 3g). Hence GD 
ligands initiate a cascade of events which ultimately triggers the activation of NADPH oxidases.  
We then investigated the effects of GD ligands in intact mice. POM1 or IgG were 
stereotactically injected into the cerebella of tga20 and Prnpo/o mice (Fig. 4a, Supplementary Fig. 
12a). Sequential manganese-enhanced magnetic resonance imaging (MEMRI)20 revealed 
hypointense lesions indicative of edema formation arising at 4-72h post-injection. At their peak, 
such lesions occupied up to 2.5% and 20% of the total cerebellar volume of wt and tga20 mice, 
respectively (Fig. 4a, b and Supplementary Fig. 12b). Histology revealed CGC chromatin 
condensation beginning at 5h post-injection (Supplementary Fig. 13a), conspicuous tissue edema 
by 24h (Supplementary Fig. 13b), and pyknotic CGC death with limited perifocal hemorrhages 
by 72h (Fig. 4a). After one week, we found substantial neuronal loss and glial scars 
(Supplementary Fig. 13c). No such changes were observed in IgG-treated tga20 or POM1-treated 
Prnpo/o mice (Fig. 4a, b, and Supplementary Fig. 13). Hypointense lesions also arose after 
stereotactic injection of POM1 or D13 into tga20 hippocampi, histologically identified as sites of 
extensive degeneration of CA3 and dentate gyrus neurons (Supplementary Fig. 14). 
Intracerebellar injection of scFvPOM1 also induced extensive lesions in tga20 cerebella and smaller 
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lesions in wt cerebella (Fig. 4c). Lesions did not arise when scFvPOM1 was pre-incubated with 
rmPrP23-230, and when scFvPOM1 was administered to Prnpo/o mice (Fig. 4c). ScFvPOM2 was 
innocuous to tga20 mice (Fig. 4c). Hence these in vivo results confirm that toxicity was 
dependent on GD binding and on PrPC expression levels, but neither on antigen crosslinking nor 
on any antibody effector functions. As with COCS, neuron-restricted PrPC expression sufficed to 
confer scFvPOM1 susceptibility in vivo (Fig. 4d), whereas mice expressing PrPΔ32-9315 were 
resistant to scFvPOM1 toxicity despite higher PrPΔ32-93 expression, PrPΔ94-110 mice16 lacking only 
the CC2 domain of PrPC experienced toxicity (Fig. 4e and Supplementary Figs. 4b and 9c).  
Mice expressing PrPΔ94-134, which lacks the central domain of PrPC, develop spontaneous 
neurodegeneration whose pathogenesis is poorly understood7 (Supplementary Fig. 9a). If this 
pathology were mediated by the FT, it might be alleviated by anti-FT antibodies. Indeed, a single 
intraventricular injection of POM2 to newborn (P0) PrPΔ94-134 mice resulted in significantly 
increased median survival (26 vs. 22 days, n=9; Fig. 4f), suggesting that the FT is also involved 
in the neurotoxicity of these PrPC mutants. 
To determine whether ROS were involved in POM1 neurotoxicity in vivo, we 
administered the enterically activated antioxidant, acetylated hydroxytyrosol21 (AcHyt) to tga20 
mice. Five of six untreated, but only one of six AcHyt-treated, tga20 mice developed cerebellar 
lesions upon scFvPOM1 injection (Fig. 4g; Supplementary Fig. 15). POM1-treated NADPH 
oxidase 2 (NOX2) deficient mice22 displayed much smaller lesions than POM1-treated wt 
controls (Fig. 4h), implicating NOX2 as the crucial source of ROS in this model.  
The data reported above uncover a critical role for the FT as the effector domain of PrPC-
mediated neuronal death. FT-mediated toxicity appears to arise from inappropriate gain of 
deleterious functions, rather than loss of homeostatic interactions, because shortening or steric 
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masking of the FT conferred protection from neurotoxicity (Supplementary Fig. 1a-b), and 
because most Prnp transgenes bearing interstitial FT deletions5,15,23 are innocuous. Similar 
mechanisms may be operative in mice24 and humans25-27 expressing PrPC variants with 
supernumerary OR (Supplementary Fig. 1c). These syndromes are surprising since the OR lie 
outside the PrPSc amyloid core and are dispensable for prion generation15,23. If the disease caused 
by supernumerary OR is mechanistically equivalent to that elicited by GD ligands, agents 
effective against GD ligand toxicity may also be beneficial to patients with OR insertions.  
Might the toxicity of GD ligands also emulate the docking of PrPSc to PrPC? This 
conjecture is supported by the role of activated calpains, which are involved in prion infections. 
Perhaps PrPSc oligomers engage PrPC through its α1/α3 helices similarly to the GD ligands 
(Supplementary Fig. 1c). In this scenario soluble PrPC may reduce prion toxicity28 by intercepting 
oligomers and preventing them from interacting with membrane-bound PrPC. Furthermore, the 
dramatic effects of GD ligands in vivo suggest that anti-GD autoimmunity may cause 
neurological conditions, and that it may be worthwhile screening patients with idiopathic 
neurodegeneration for such autoantibodies.  
 
Methods summary 
Slices were prepared using a vibratome from 10-12 old-days pups according to a previously 
published protocol9. Viability was assessed by quantifying propidium iodide incorporation or 
NeuN immunoreactive area using analysis software analySIS vs5.0. F(ab)1 and F(ab)2 fragments 
were generated by ficin digestion, isolated after protein A elution and further purified by size 
exclusion chromatography. Single chain fragments of POM1 and POM2 were expressed in 
Escherichia Coli (periplasm) and purified by Ni-NTA agarose columns. Recombinant mouse 
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prion proteins (23-230 and 90-230) were generated in bacteria and purified as reported29,30. The 
POM1 epitope was determined by X-ray and NMR analyses as described in the Supplementary 
Methods section. Antibodies and respective fragments were stereotactically injected into mouse 
brains; lesions were visualized by MEMRI and quantified with Para Vision software (Version 5. 
Opl3, Bruker). SPR experiments were performed with a BIAcore X100 instrument and 
interpreted with BIAcore T100 Evaluation Software, version 2.0.3. 
 
A detailed description of methods and materials is given in the Supplementary Information 
section. 
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Figure legends 
Figure 1. Epitope specificity of the neurotoxicity mediated by antiprion antibodies. a, 
Antibody binding sites on rmPrP23-230. POM6-9, 13, 15 and 17 bind helix α1 and compete with 
POM13. POM6 and POM7 (light orange) show additional binding sites at helix α2 (dark orange), 
whereas POM5 recognizes a unique epitope at the β2-α2 transition (green, Supplementary Table 
2). GD image was rendered using the PDB structure 2L1H. b, NeuN morphometry of tga20 
COCS treated with various antibodies to FT and GD epitopes (same color codes as in panel a). 
Treatment modalities: 67 nM, 10 days (&); 200 nM, 21 days (); 333 nM, 14 days ($), or 67 nM, 
21 days (unlabeled columns). CGC loss was induced by antibodies to helices α1 (light violet, 
orange, red) and α3 (blue). Antibodies binding the CC2 (magenta) were toxic only at higher 
concentrations and after protracted incubation. Antibodies against the OR (turquoise) were 
consistently innocuous. Ordinate: percentage of NeuN+ pixels within the CGC layer, normalized 
against treatment with pooled IgG. One-way ANOVA with Dunnett’s post-test, ***P<0.001, 
**P<0.01, mean ± s.d, n=9 biological replicates.  
 
Figure 2. Antibody-mediated toxicity in cerebellar slices does not require crosslinking or 
antibody effector functions. a, Tga20 COCS were treated with POM1 (67 nM) or with pooled 
IgG (67nM, used here and in all following figures as negative control) for 14 dpe, cut 
transversally as indicated in the left panel, and stained with hematoxylin and eosin. POM1 
treatment caused COCS thinning and CGC ablation. Arrows: Purkinje cells. b, Tga20 COCS 
were exposed to POM1 or to control pooled IgG (67 nM, 10 dpe), immunostained for the 
neuronal marker NeuN, and imaged by confocal laser scanning microscopy. POM1 (lower 
panels) induced loss of NeuN immunoreactivity. c, Concentration and time-dependent CGC loss 
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in POM1-exposed tga20 (left panel; 14 dpe) and wt COCS (right panel; antibody concentration: 
270 nM). One-way-ANOVA with Dunnett’s post-test. d, Preincubation of POM1 with 
rmPrP23-230 (molar ratio 1:60) suppressed neurodegeneration of tga20 COCS (antibody treatment: 
67 nM, 14 dpe). One-way-ANOVA with Tukey’s post-test. e, COCS were treated with POM1 
(67 nM) and scored for NeuN+ (blue) and PI+ (red) area coverage within the CGL. PI 
incorporation peaked at 3 dpe, coinciding with the maximum slope of NeuN decay. f, Prnpo/o and 
tga20 COCS were incubated with POM1 holoantibody, divalent F(ab)2, monovalent F(ab)1, or 
scFv derivatives of POM1. NeuN morphometry identified severe neurodegeneration after 
exposure (10 dpe) to each ligand irrespectively of its valence. Red dashed lines (here and 
henceforth) delineate independent experiments normalized against their respective IgG control 
assays. One-way-ANOVA with Dunnett’s post-test. g, Treatment of tga20 COCS for 21 days 
with F(ab)1 fragments of POM17 and 19 (134 nM) resulted in similar toxicity as with 
holoantibodies, whereas F(ab)1POM5 and F(ab)1POM15 were innocuous. One-way-ANOVA 
with Tukey’s post-test. For all experiments, data in bar charts are presented as mean ± s.d, n=9 
biological replicates; ***P<0.001. 
 
Figure 3. Neuroprotection against GD ligand toxicity. a, NeuN morphometry of COCS treated 
with POM1 antibody (167 nM, 28 dpe). Wt and PrPΔ94-110 COCS (line L46), but neither PrPΔ32-93 
nor Prnpo/o COCS, experienced POM1 toxicity. One-way-ANOVA with Tukey’s post-test. b, 
Tga20 COCS were pre-treated with various antibodies directed against the FT (37°C, 30 min) and 
exposed to POM1 (yellow bars: 67 nM, 14 dpe). POM2, POM11, POM3 and D13 (67 nM) 
prevented POM1 toxicity. White bars: omission of POM1. One-way-ANOVA with Dunnett’s 
post-test. c, Pre-treatment with scFvPOM2 (264 nM) protected tga20 COCS from scFvPOM1 (264 
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nM; 10 dpe). One-way-ANOVA with Dunnett’s post-test. d, Effect of various compounds (listed 
in Supplementary Table 4) on POM1 toxicity (67 nM). Compound concentrations are reported in 
Supplementary Information. Yellow: no pre-treatment. Red: protective compounds. White: non-
protective compounds. Grey: IgG control-treated slices. POM1 neurotoxicity was blocked by 
antioxidants and calpain inhibitors, but not by caspase or iNOS inhibitors. Isoascorbate, a cell 
impermeable analogue of ascorbate, was also protective. One-way-ANOVA with Dunnett’s post-
test. e, Cultures (3 dpe) were assayed for DEVDase (black) and LLYase activity (red), indicative 
of caspase and calpain activity, respectively. Protease activity was normalized to protein 
amount ± s.d. One-way-ANOVA with Dunnett’s post-test, mean ± s.d., n=3 pools of 18 slices. 
Whilst staurosporine (24h) increased both activities, POM1 treatment increased LLYase but not 
DEVDase activity. f, Immunodetection of α-fodrin in tga20 COCS (3 dpe). ScFvPOM1 treatment 
increased total α-fodrin cleavage and the calpain-specific fragment of 145 kDa (n= 3 pools of 6 
slices; mean ± s.d. underneath blot; two-tailed student t-test, P=0.0054). g, ScFvPOM1-treated 
COCS (400 nM, 24h) were harvested and analyzed for ROS production by lucigenin assay in the 
presence or absence of DPI. One-way-ANOVA with Dunnett’s post-test, mean ± s.d., n=4, each 
datapoint represents a pool of 9 slices). For all experiments, data in bar charts are presented as 
mean ± s.d, n=9 biological replicates; ***P<0.001, **P<0.01. 
 
Figure 4. Anti-PrP antibody toxicity in vivo. a, MEMRI scans showed hypointense lesions in 
POM1-treated (6 μg in 2 μl) wt and tga20 mice (left panels) 72 hours post intracerebellar 
injection (pii). Yellow dashed lines delineate the lesions. Histology (middle and right panels) 
revealed CGC destruction (stars) and edema. Rectangles: region magnified in the corresponding 
rightmost panel. Tga20 Purkinje cells (arrow), which do not express PrPC, were largely preserved. 
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b, Lesion volumes at 4, 24, and 72h pii as percentages of total cerebellar volumes in wt, tga20, 
and Prnpo/o. Grey: control injections (6 μg, mean ± s.d.,  n=4 except for Prnpo/o at 72h n=3, tga20 
at 4h and 24h n=6, one-way-ANOVA with Dunnett’s post-test). c, Lesions occurred in tga20 
(n=4) and wt (n=4) mice after injection of scFvPOM1 (2 μg) but not after scFvPOM2 (n=4), or 
scFvPOM1 (2 μg) preincubated with recombinant mPrP23-230 (molar ratio 1:5, 24h, n=4). ScFvPOM1-
treatment was innocuous to Prnpo/o (n=3) mice (mean ± s.d., two-tailed student t-test). d, MEMRI 
volumetry (24h pii) of NSE-PrP (n=4) and Prnpo/o (n=7) mice injected with scFvPOM1 (3 μg; 
mean ± s.d., two-tailed student t-test). e, MEMRI volumetry 24h pii of scFvPOM1 into 
PrPΔ94-110(L52, n=3), PrPΔ32-93 (n=5), and wt (n=8) (mean ± s.d.; two-tailed Student t-test). f, 
Survival of mice expressing a PrPΔ94-134 transgene was prolonged by intraventricular POM2 (n=9) 
treatment vs. IgG control (n=5) (4 g, Mantel-Cox-test). g, Tga20 mice 24h pii of scFvPOM1 (2 
µg) pre-treated with acetylated hydroxytyrosol, (mean ± s.d., n=6, one-tailed student t-test. P= 
0.013). h, MEMRI volumetry at 24h pii of scFvPOM1 (3 μg) into Prnpo/o (n=7), wt (n=5) and 
NOX2-deficient (n=11) mice (mean ± s.d., one-tailed student t-test).  
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Supplementary Materials and Methods 
Chemicals and mice 
All compounds were purchased from Sigma/Aldrich unless otherwise stated. GABA-Aα6-CRE 
mice were generated on a C57BL/6xCBA background and back-crossed to a Prnpo/o 
background12,31. Tg37 mice allowing for conditional PrP deletion were generated on a Prnpo/o 
FVB background32. GABA-Aα6-CRE-;loxPrP-tg37 littermates were used as negative controls 
(PrPCGC+). B6.129S6-Cybbtm1Din/J (NOX2)-deficient mice were generated on a mixed 
C57BL/6xSv129 background and backcrossed to C57BL/622. Prnpo/o, Prnpo/o;tga20+/+ (tga20), 
Prnpo/o;C4/C4 (PrPΔ32-93), Prnpo/o;1046 (PrPΔ94-134)7, Prnpo/o;L46 (PrPΔ94-110)16, Prnpo/o;L52 
(PrPΔ94-110), Prnpo/o;NSE-PrP+/+ (NSE-PrP) and Prnpo/o;MBP-PrP+/+ (MBP-PrP) mice were on a 
mixed 129Sv/BL6 background, and wt mice on a C57BL/6 background5,12,15,16,33,34. Prnpo/o;L52 
(PrPΔ94-110) was previously reported16. CD11b-HSVTK mice35 on a C57BL/6 background were 
crossed to Prnpo/o;tga20+/+. All offspring were Prnp+/o;tga20+ and CD11b-HSVTK positive 
offspring were referred to as tga20TK+. All mouse experiments were performed on 6-9 month old 
males and females, conformed to Swiss law, and were approved by the Animal Experimentation 
Committee of the Canton of Zurich (permits 200/2007 and 130/2008).  
Animal surgery 
Mice were anesthetized with isoflurane and placed in a motorized stereotaxic frame controlled by 
software with a 3D brain map, allowing for real-time monitoring of needle placement 
(Neurostar). The skull was exposed by cutting along the midline and a small hole was drilled 
using a surgical drill and the needle mounted in an electronic micro-injector unit was placed for 
cerebellar injection at the following lambda coordinates: AP -2.3mm, ML 0mm, DV 2mm and for 
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hippocampal injection at the following bregma coordinates: AP -2mm, ML 1.7mm, DV 2.2mm, 
angle in ML/DV plane 15°. Antibodies (2 μl) were injected at a flow-rate of 0.5 μl min-1 and the 
needle was left in place for 1 min. Mice were sutured and received an injection of 
buprenorphinum (0.1 μg g-1 bodyweight). 
Hydroxytyrosol treatment 
Mice were treated with acetylated hydroxytyrosol starting 7 days prior to injection with 2g l-1 in 
drinking water.  
Newborn injections 
Newborn mice (P0) were injected with a thin Hamilton syringe into the lateral ventricle (2 µL of 
2 mg ml-1 IgG or POM2 solution into each hemisphere) according to previously reported 
protocols36.  
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) 
Mice received five intraperitoneal injections of MnCl2 (40 mg kg-1, 20 mM in H2O and bicine, 
pH 7.4) at 12h intervals37. The last injection was administered immediately after the stereotaxic 
injection. Mice were imaged under isoflurane anesthesia at 4h, 24h and 72h post-surgery in a 4.7-
Tesla small-animal MRI system (Bruker Pharmascan). Mice were placed in a bed equipped with 
a mouse whole-body radio frequency transmitter coil and a mouse head surface-coil receiver 
(Bruker Pharmascan). Body temperature was maintained with a warming blanket. T-1 weighted 
brain images were obtained using a 3D gradient-echo sequence (TR: 15 ms, TE: 2.5 ms, FA: 20 
deg, Average:10, Matrix: 265/265/126, Field of View: 2x2.56x2 cm3, acquisition time: 1h, voxel 
size: 78x100x156 μm3)38.  
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Quantification was performed with ParaVision software (Version 5. Opl3, Bruker). Cerebellar 
lesions were quantified by two region of interests (ROIs) corresponding to the lesioned and total 
cerebellar area were set for each optical slice of the 3D dataset. For hippocampal lesion 
quantification, the volume of non-affected CA3 was measured. ROIs were set on the ipsilateral 
and contralateral side of injection. Volumes for each ROI were calculated by multiplying the sum 
of the ROI area times the voxel height. Data are presented as the lesion volume divided by the 
total cerebellar volume, i.e. lesion volume (%) or as CA3 volume (mm3), separated by ipsilateral 
versus contralateral side.  
Organotypic brain culture preparation 
Organotypic cerebellar slice cultures, 350 µm thick, were prepared from 10-11 day-old pups 
according to a previously published protocol9. Free-floating sections were cut in Gey’s balanced 
salt solution (GBSS) (NaCl 8 g l–1, KCl 0.37 g l–1, Na2HPO4 0.12 g l–1, CaCl2 2H2O 0.22 g l–1, 
KH2PO4 0.09 g l–1, MgSO4 7H2O 0.07 g l–1, MgCl2 6H2O 0.210 g l–1, NaHCO3 0.227 g l–1) 
supplemented with the glutamate receptor antagonist kynurenic acid (1 mM) (GBSSK) at 4°C. 
Slices were placed on a 6-well Millicell-CM Biopore PTFE membrane insert (Millipore). 
Residual buffer was removed and the inserts were transferred to a cell culture plate and cultured 
in “slice-culture medium” (50% vol/vol MEM, 25% vol/vol basal medium Eagle and 25% vol/vol 
horse serum supplemented with 0.65% glucose (w/vol), penicillin/streptomycin and glutamax 
(Invitrogen)). Cultures were kept in a standard cell incubator (37°C, 5% CO2, 95% humidity) and 
the culture medium was exchanged three times per week.  
Antibody treatment was randomly assigned to individual wells and initiated after a 10-14 day 
recovery period allowing the initial gliosis induced by tissue preparation to subside. Slices were 
harvested for biochemical analyses or fixed for immunocytochemical analysis at various time 
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points. For microglia depletion experiments, tga20TK+ slices were treated with ganciclovir (GCV, 
5 μg ml-1) for 14 days prior to antibody treatment. At this time point less than 1% of microglia 
were left in the tissue39.  
Pharmacological treatment of COCS  
Drug treatment was initiated at the time of antibody addition and drugs were re-added at every 
medium change. Appropriate drug concentrations were determined by literature search, assuming 
that slice culture uptake of compounds were similar to other cell culture systems. The toxicity of 
each compound was tested in parallel on IgG and POM1 slices; if toxicity occurred, drugs were 
retested at a lower concentration. Drug and concentration used were  ascorbate (1.5 mM), 
isoascorbate (1.5mM), MnTBAP (100 μM), benzyloxycarbonyl-Val-Ala-Asp (OMe) 
fluoromethylketone (zVAD-fmk, 40 μM), diphenyleneiodonium chloride (DPI, 5 μM), N-([3-
(Aminomethyl)phenyl]methyl)- ethanimidamide dihydrochloride (1400W, 20 μM), N-
benzyloxycarbonyl-L-leucylnorleucinal (calpeptin, 20 μM), N-acetylcystein (NaC, 1 mM).  
Protein analysis 
COCS were washed twice in PBS. Cerebellar tissue was then scraped off the membrane using 10 
µl per slice of PBS with 0.5% DOC, 0.5% NP-40 supplemented with PMSF (1 μM) and complete 
mini protease inhibitor cocktail (Roche), and homogenized by trituration using a 30G syringe. 
Protein concentration was determined using the bicinchoninic acid assay (Pierce). Samples were 
prepared in loading buffer (NuPAGE, Invitrogen) and boiled at 95°C for 5 min. Proteins (10 μg 
per lane) were separated on a 12% Bis-Tris polyacrylamide gel or for higher molecular weight 
proteins on a 4-12% gradient gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose 
membrane. Membranes were blocked with 5% w/vol Topblock (Fluka) in Tris-buffered saline 
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supplemented with Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) and 
incubated with primary antibodies in 1% Topblock. Primary mouse monoclonal antibodies used 
were: POM1, POM2, mouse IgG1 antibody raised against PrPC (anti-PrPC; 200 ng ml–1), mouse 
anti-α-fodrin (AA6, 100 ng ml-1, Millipore) and anti-GAPDH (200 ng ml-1, Millipore). Secondary 
antibodies were horseradish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, 
Zymed), goat anti–rabbit IgG1 (1:10,000, Zymed), and rabbit anti–goat IgG1 (1:10,000, Zymed). 
Blots were developed using SuperSignal West Pico chemiluminescent substrate (Pierce) and 
visualized using the VersaDoc system (model 3000, Bio-Rad).  PNGase treatment was performed 
using a commercially available kit, according to the manufacturer’s protocol (New England 
Biolabs). In brief, 10 μg protein was treated with 2 μl denaturation buffer in a 20 μl reaction and 
incubated for 15 min at 95°C. A reaction mixture of 2.6 μl G7, 2.6 μl NP-40 (10%), as well as 0.5 
μl PNGase was added and samples were incubated for 2h at 37°C. Samples were then mixed with 
loading dye, cooked and analyzed by western blotting. Cerebella from 10 day-old pups were 
homogenized (10% w/v) in  0.32 M sucrose in 1x PBS supplemented with 4-(2-Aminoethyl)-
Benzene sulfonyl fluoride HCL (AEBSF, 1 mM) and complete mini protease inhibitor cocktail 
(Roche) using a tissue Ribolyser (Qiagen).  PrPC expression in the brains of PrP deletion mutants 
was analyzed by PrP-specific sandwich ELISA3.  Briefly, samples were incubated in POM1-
coated ELISA plates (overnight at 4°C). Plates were then washed and incubated with biotinylated 
POM19 (1.6 ng ml-1) for 1h at 37°C. Avidin-HRP (1:1000) (BD-Pharmigen) was used as 
detection antibody (1h, 37°C). After 3 washes, stabilized chromogen (Invitrogen) was added, 
incubated for 30 minutes at 37°C, and absorbance was read at 450 nm. All samples were 
analyzed at dilutions falling within the logarithmic range of the calibration curve (rmPrP23-230: 
0.62-80 ng ml-1).  
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Generation of POM monoclonals, F(ab)1POM1  and F(ab)2POM1 fragments 
POM monoclonal antibodies were generated as published3. F(ab)1POM1 and F(ab)2POM1 
fragments were generated by ficin digestion and purified on a protein A column according to 
manufacturer’s protocol (Pierce). Protein A flow-through containing F(ab)1POM1 was collected, 
concentrated by Amicon ultra-15 centrifugal units (Millipore). F(ab)1POM1 was further purified 
by size exclusion chromatography (Superdex75 10/300 GL, GE Healthcare) using PBS and a 
flow rate of 0.5 ml min-1. Pure fractions were pooled, concentrated and stored at -20°C. The 
concentrations of the IgG and F(ab)1POM fragments were determined by measuring their 
absorbance at 280 nm in a UV-VIS photometer using an extinction coefficient (E) 0.1% at 280 
nm of 1.35. Aldolase (158 kDa), conalbumin (75 kDa) and ovalbumin (43 kDa) were used as 
control molecular weight markers. The purity of the fragments was checked by Coomassie-
stained SDS PAGE. 
For Kd determination, F(ab)1POM fragments were generated from the POM antibodies using 
immobilized papain (10-20 mg of mAb ml-1 of immobilized papain as packed resin) activated in 
digestion buffer (20 mM sodium phosphate, 10 mM EDTA, 20 mM cysteine hydrochloride, pH  
7.0) according to the manufacturer’s instructions (Pierce, Rockfort, IL). The reaction mixture was 
incubated overnight with rigorous shaking at 37°C. The digest was separated from the 
immobilized papain with a resin separator. The immobilized papain was then washed with 
binding buffer (Protein A IgG Binding Buffer, Pierce) which was added to the digest. 
To remove undigested IgG and Fc fragments from the F(ab)1 fragments, the digest was loaded 
onto a 2 ml Protein A plus Agarose column (Pierce), equilibrated in binding buffer, and washed 
with 6 ml binding buffer. The F(ab)1-containing flow-through and wash fractions were pooled 
and further purified by size exclusion chromatography as described above. 
24 | P a g e  
 
Periplasmic expression and purification of scFvPOM1, scFvPOM2, rmPrP23-230 and rmPrP90-
230: 
For periplasmic expression and purification of scFvPOM2, the pET-22b(+) vector (Novagen) was 
used, as it has both periplasmic localization and C-term 6xHis tag sequences. The scFvPOM2 
gene, constructed previously using the phage display method3, was inserted into the pET-22b(+) 
vector between the restriction sites- EcoRI and XhoI. The resulting plasmid was transformed into 
competent RosettaTM (DE3) pLysS cells by heat-shock.  
A fresh, single colony of transformed Rosetta cells was inoculated in 2xYT media with 100 g 
ml-1 Ampicillin and 34 g ml-1 Chloramphenicol (2xYT-AC media) and grown overnight at 37C 
at 250 rpm. The overnight culture was further propagated (1:1000) in fresh 2xYT-AC media until 
the OD600 reached ~0.4-0.5. The culture was then cooled down to 25C in a cold water bath and 
induced with Isopropyl -D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. 
The induction was allowed to continue overnight at 25C and 250 rpm. The cells were harvested 
and resuspended in 50 ml l-1 of the original culture volume of freshly prepared, pre-chilled 
periplasmic extraction buffer [200mM Tris-HCl, 20% (w/v) sucrose, 1 mM EDTA pH-8.0] and 
incubated on ice for 1 hour with occasional stirring. The suspension was spun down at 15,000xg 
for 30 min at 4C and the supernatant was collected as the soluble protein extract. The extract 
was thoroughly dialyzed against 50 mM Tris-HCl, 100 mM NaCl, pH 7.0 at 4°C and further 
clarified by centrifugation at 15,000xg for 30 min at 4°C40.  
The clarified soluble protein extract was loaded onto a Ni-NTA agarose (Qiagen) column 
equilibrated with 50 mM Tris and 100 mM NaCl, pH 7.0. The unbound protein and impurities 
were washed off with 50 mM Tris, 100 mM NaCl and 50 mM Imidazole pH 7.0 and the elution 
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was performed with 50 mM Tris, 100 mM NaCl and 500 mM Imidazole pH 7.0. The purity of the 
eluates was checked using gel electrophoresis. Pure scFvPOM2 samples were dialyzed against 50 
mM Tris, 100 mM NaCl and 50 mM Imidazole pH 7.0 and concentrated to ~3 mg ml-1. The same 
procedures applied to expression and purification of periplasmic scFvPOM1 except the induction 
was at 17°C. Recombinant mouse PrP was generated in bacteria and purified as reported 
elsewhere29,41.  
SPR measurements and binding affinity determination 
Aminoterminal truncated rmPrP90-230 and full-length rmPrP23-230 were immobilized on a 
carboxymethylated-dextran sensor chip (CM5, Biacore) by standard EDC/NHS chemistry. The 
amount of protein immobilized on the surface corresponded to 1000 Resonance Units (RU) of 
rmPrP23-230 and 4600 RU of rmPrP90-230 for comparing F(ab)1POM1 binding in the absence of the 
OR.  For comparing different F(ab)1 affinities, a density of 100 RU of rmPrP23-230 was used 
(Supplementary Table 1). Various concentrations of F(ab)1 measurements were performed on a 
Biacore T100 at 37°C. F(ab)1 fragments, diluted in running buffer (HBS-EP+), and at a 
concentration range of 0.01-5.12 nM were injected for 350s at a flow rate of 30 μl min-1. The 
sensor surface was regenerated between each measurement with 20 mM NaOH. Binding affinity 
was determined by using the instrument software (Biacore T100 Evaluation Software, version: 
2.0.3).  
Immunocytochemistry 
For immunocytochemistry, organotypic slices were washed twice in PBS and fixed in 4% 
formalin overnight at 4°C. Membrane inserts were washed and incubated for 1 h in blocking 
buffer (0.05% vol/vol Triton X-100 and 3% vol/vol goat serum dissolved in PBS) and incubated 
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with conjugated mouse anti-NeuN-Alexa488 (0.5 μg ml-1, Millipore) antibody diluted in blocking 
buffer at 4°C for 3 d. Inserts were washed four times with PBS and counterstained with 4,6-
diamidino-2-phenylindole (dapi) (1 µg ml–1). For NeuN morphometry images were recorded at 
4x magnification on a fluorescence microscope (BX-61, Olympus) equipped with a cooled 
black/white CCD camera at identical exposure times. The area of immunoreactivity was 
determined by morphometry with image analysis software analySIS vs5.0 using identical 
greyscale threshold settings for identifying positive pixels.  
Mice were euthanized after the last scan (either 5, 24 or 72 hours post injection) and brains fixed 
in 4% formalin. Cerebella were paraffin embedded and 2µm coronal sections were cut and 
stained. Hematoxylin and eosin staining and NeuN immunohistochemistry were performed 
according to standard protocols.  
Proteolytic assays 
Slices were harvested in pools of 18 slices in PBS, 0.5% DOC, 0.5% NP-40 with 2% β-
mercaptoethanol and homogenized by trituration. Homogenates were analyzed immediately for 
DEVDase activity using caspase 3 fluorometric detection kit (Enzo Life Sciences Caspase-3 
Activity Assay kit) and normalized to protein concentration. Slices (pools of 18) were 
homogenized and processed according to the manufacturer's instructions (Biovision Calpain 
Activity Assay kit). Calpain activity (Ac-LLY-ase) was measured by detecting cleavage of a 
specific fluorogenic calpain substrate, Ac-LLY-AFC on a fluorescence plate reader (360-nm 
excitation filter, 440-nm emission filter) and normalizing to protein amount. 
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Electron microscopy 
Slices were washed in Na-phosphate buffer, fixed in freshly prepared 2% PFA + 2.5% GA in 0.1 
M Na-phosphate buffer 0.1 M pH 7.4, postfixed in 1% osmium tetroxide for 1-2 hours, 
dehydrated through a series of graded ethanols and propylene oxide, embedded in Epon and 
processed for electron microscopy using standard procedures. Grids were examined and 
photographed in JEOL JEM 100 CX and JEOL JEM 1011 transmission electron microscopes at 
80 kV. Nuclear morphology (as presented in Supplementary Figure 10) was determined by 
counting 11 fields in IgG-treated COCS at 3, 7, and 10 dpe. For POM1-treated COCS, 10 fields 
at 3 dpe, 12 fields at 5 and 10 dpe, were analyzed. For assessing necrotic, apoptotic and 
normal POM1-treated slices at 7 dpe, 15, 16 and 20 fields were counted, respectively. 
 
Viability and ROS assays 
For propidium iodide (PI) incorporation, slices were incubated for 30 min with PI (5 μg ml-1) and 
images were recorded in living tissue using a fluorescent microscope (Axiovert 200) equipped 
with a cooled CCD camera using a 5x objective and analyzed by morphometry. Lucigenin 
conversion assay was performed at room temperature as follows: Inserts containing 5-10 slices 
each were washed in PBS and harvested in Krebs-Ringer solution supplemented with complete 
mini protease inhibitor cocktail (Roche). Samples were triturated with a 30G syringe, and 50 μl 
of each sample was mixed with 175 μl assay buffer and 0.25 μl lucigenin (10 mM). Background 
activity was measured using a chemiluminescence reader. Subsequently, 50 μl NADPH (1 mM) 
was added to each well and the plate was read again. Background activity was subtracted from 
the NADPH dependent signal and data (each bar: average of 4 inserts ± s.d.) are presented as 
relative light unit mg-1 total protein. 
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Erythrocyte complement lysis assay 
1 ml tail vein blood was collected from Prnpo/o and Prnpo/o;tga20+/+ mice in 50 μl, 0.5 M EDTA 
on ice. Red blood cells (RBCs) were pelleted (2000 RPM for 10 min at RT) and washed in ice-
cold PBS thrice. RBCs were resuspended cells in GVB2+ buffer (0.15 mM CaCl2, 141 mM NaCl, 
0.5 mM MgCl2, 0.1% gelatin, 1.8 mM sodium barbital and 3.1 mM barbituric acid, pH 7.3 and 
aseptically filtered) and sensitized to complement lysis by incubation with complement activating 
antibody (34-3C42, 100 μg ml-1 final concentration) or different POM antibodies (100 μg ml-1 
final concentration) for 1h at RT. RBCs were washed in ice-cold PBS thrice, resuspended in 
GVB2+ buffer and 5 x 107 cells were incubated with different concentrations of serum diluted in 
GVB2+ buffer in a total volume of 125 μl. RBCs were incubated for 30 min at 37°C, pelleted by 
centrifugation and 100 μl supernatant was transferred to a transparent 96 well plate and the 
absorbance at 414 nm was determined. Relative lytic activity was defined as the serum dilution 
factor leading to 30% erythrocyte lysis, calculated from the fitted serum dilution curves. 
Protein expression and isotopic labelling 
For the expression of uniform [2H,15N]-labeled rmPrP23-230, M9 medium was produced from D2O. 
M9 medium was supplemented with magnesium chloride, vitamins, ampicillin (final 
concentration: 100 µg ml-1) and ammonium chloride (2g l-1). The main culture was started by 
transferring cells from a 2l preculture of LB medium grown to an OD 1.6 at 37°C into 2 liter of 
M9 D2O medium. Cells were further incubated for 1h at 37°C and induced by addition of 1 mM 
IPTG. After 6h cells were harvested and rmPrP23-230 was purified according to our standard 
protocol29,43. 
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NMR experiments  
The [15N,2H]- transverse relaxation optimized spectroscopy (TROSY) NMR44 experiments of the 
free 2H,15N-labeled rmPrP23-230 and in complex with scFvPOM1 were performed on a Bruker 
Avance 700 MHz spectrometer equipped with a 5 mm triple-resonance cryoprobe and a single 
pulsed field gradient in 10 mM sodium phosphate, pH 7.3, and 5% (v/v) D2O at 20°C. The data 
were processed by the software XwinNMR, version 3.5 (Bruker, Germany) and further analysed 
by the program CARA (www.nmr.ch)45. For the assignment of residues 89-230 the assignments 
deposited in the BioMagResBank (accession numbers: mPrP90–231, 16071; numeration according 
to human PrP) were used, whereas for residues 23-88 a tentative assignment was performed 
based on the available assignments at pH 4.546.  
Statistical analysis of COCS 
One-way ANOVA with Tukey’s post-test for multi-column comparison, or Dunnett’s post-test 
for comparison of all columns to a control column, were used for statistical analysis of 
experiments involving the comparison of three or more samples. Paired Student’s t-test was used 
for comparing two samples. Results are displayed as the average of replicas ± s.d.  
Statistical analysis of MEMRI data sets 
For statistical analysis of experiments involving the comparison of three or more data sets, we 
used one-way ANOVA with Dunnett’s post-test for comparison of all data sets to a control data 
set. One or two-tailed unpaired Student’s t-test was used for comparing two data sets. Results are 
displayed as mean ± s.d. *: P<0.05; **: P<0.01; ***: P<0.001, ****: P<0.0001. 
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Data collection and structure determination 
Diffraction quality POM1 F(ab)1:rmPrP120-230 protein complex crystals were grown by the vapor 
diffusion method at room temperature as described by Baral et al 47. X ray diffraction data were 
measured at the Stanford Synchrotron Radiation Laboratory (SSRL), beamline 9-248,49,50. The 
data were processed in space group C2 to a resolution of 1.9Å using the program HKL200051. 
The data collection details as well as the refinement statistics are presented in Supplementary 
Table 3. The structure of POM1 F(ab)1:rmPrP120-230 protein complex was solved by the molecular 
replacement method using the program MOLREP52 of the CCP4 package 53. The coordinates of 
POM1 F(ab)1:huPrP120-230 protein complex, protein data bank (PDB ID: 4DGI), were used as the 
template. Solution from the molecular replacement was then refined by restrained refinement, 
implemented in the refinement program of the PHENIX package 54. The progress of the 
refinement process was monitored by a reduction in both the Rwork and Rfree factors to final values 
of 19.9% and 23.4%, respectively. Solvent molecules are added to the model by an automated 
PHENIX program and those water molecules were accepted only when well defined positive 
peaks were present in both the 2|Fo|-|Fc| and |Fo|-|Fc| electron density maps and there was a 
satisfactory hydrogen-bonding network with either protein atoms or other water molecules. 
Model building was performed with the program COOT55. The final structural coordinates for the 
POM1 F(ab)1:rmPrP120-230 complex were validated with MOLPROBITY56 and deposited in the  
RSCB PDB (accession code 4H88) along with the structure factors. MOLPROBITY showed that 
96.8% of the amino acid residues were in the most favored region of the Ramachandran plot.  All 
illustrations were created with the program Pymol (www.pymol.org).  
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Supplementary tables 
Supplementary Table 1. Table of abbrevations in alphabetic order. 
CC2 Charge cluster 2 (residues 94 – 110) 
CGC Cerebellar granular cells 
COCS Cerebellar organotypic slice culture 
dpe Days post-exposure 
F(ab) Fragment antigen binding 
FT N-proximal Flexible tail of PrPC (residues 23 – 124) 
FT / GD ligands Holoantibodies, monovalent F(ab)1 fragments, divalent F(ab)2 fragments and recombinant 
single-chain antibodies (scFv) binding to the flexible tail or globular domain  
GD Globular domain of PrPC (residues 124 – 230) 
MEMRI Manganese Enhanced Magnetic Resonance Imaging 
NMR Nuclear Magnetic Resonance 
NOX2 NADPH oxidase 2 
OR Octapeptide repeats (residues 50-90) 
PI Propidium iodide 
pii Post intracerebellar injection 
POMs Set of 19 anti PrP monoclonal antibodies (Polymenidou 2008) 
Prnp PrP gene locus 
Prnp°/° Mice lacking the Prnp gene 
PrP, PrPC, PrPSc Prion protein, cellular Prion protein, Scrapie-associated Prion protein 
PrPΔ32-93, PrPΔ94-110 Transgenic mice expressing a truncated PrP version (lacking residues 32-93 and 94-110, 
respectively) 
rmPrP23-230 Full length recombinant mouse PrP (residues 23-230) 
ROS Reactive oxygen species 
ScFv Single-chain variable fragment 
tga20 Mice overexpressing PrPC 
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Supplementary Table 2. Synopsis of the antibodies targeting PrP. 
 Domain* Epitope* Toxicity# 
GD 
protection           Affinity (nM) 
  sequence location   Holo-Ab F(ab)1 scFv 
POM2 FT GQPHGGG/SW 57-64, 64-72, 
72-80, 80-88 
- + <0.1* 2.5 20* 
POM11 FT GQPHGGSW 64-72, 72-80 - +  - - 
POM12 FT GQPHGGG/SW 57-64, 64-72, 
72-80,80-88 
-   - - 
POM3 HR HNQWNK 95-100 +/- +  - - 
POM1 GD β1-α1 loop, α1  
and α3 
¥138-147; 
204/208/212 
+  0.58* 2.5 800 
POM4 GD β1 and α3 121-134 and 
218-221 
+   - - 
POM5 GD β2-α2 loop, α2 168-174 -   16 - 
POM6 GD β1-α1 loop, α1 
β2-α2 loop, α2 
140/145; 
158/177; 
170/174 
-   - - 
POM7 GD β1-α1 loop, α1 
β2-α2 loop, α2 
140/145; 
158/177; 
170/174 
-   - - 
POM8 GD β1-α1 loop, α1 
β2-α2 loop, α2 
140/145; 
170/174 
+   - - 
POM9 GD β1-α1 loop, α1 
β2-α2 loop, α2 
140/145; 
170/174 
+   - - 
POM10 GD β1 and α3 121-134 and 
218-221 
+   -  
POM13 GD α1  +/-   -  
POM15 GD β1-α1 loop, α1 140/145 -   5  
POM17 GD β1-α1 loop, α1 140/145 +   6.6  
POM19 GD β1 and α3 121-134 and 
218-221 
+  0.87* 0.4  
 
*: data from ref.3, reproduced here for convenience. The reported epitopes are based on peptide 
competition and differential binding to PrPC mutants. For POM1, crystallographic coordinates 
were used. ¥: The POM1 epitope was characterized by X-ray analysis (Movie S1) and NMR 
spectroscopy (Supplementary Fig. 9) and revealed an additional contact site on helix3. #: +: toxic; 
-: nontoxic; +/-: moderately toxic  
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Supplementary Table 3. Crystallographic analysis of the POM1-PrP complex: data collection 
and refinement statistics. 
 
 POM1 F(ab)1:rmPrP120230 
Data collection  
Space group C2 
Cell dimensions  
    a, b, c (Å) 83.4, 107.3, 75.4 
 ()  90.0, 95.2, 90.0 
Resolution (Å) 50-1.90 (1.97-1.90) * 
Rmerge 0.08 (0.52) 
I/I 4.2 (3.9) 
Completeness (%) 96.0 (74.1) 
Redundancy 4.2 (3.9) 
  
Refinement  
Resolution (Å) 50.0-1.90 
No. reflections 49,880 
Rwork/ Rfree 0.19/0.23 
No. atoms  
    Protein 4153 
    Ligand/ion 1 
    Water 359 
B-factors  
    Protein 42.2 
    Ligand/ion 12.8 
    Water 43.7 
R.m.s deviations  
    Bond lengths (Å)  0.006 
    Bond angles (º) 0.956 
Number of crystals =1.  
*Highest resolution shell is shown in parenthesis.  
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Supplementary Table 4. Description of the tool compounds used in the study. 
Compound Primary target  
(according to published data) 
  Protection 
against 
POM1 
1400W Nitric oxide synthase 1 and 2 57 no 
Ascorbate ROS scavenging 58 yes 
 
Calpeptin Cysteine-proteases: Calpains and         
cathepsins 59,60 
 
yes 
DPI NOX inhibitor 61  n/a 
 
Isoascorbate 
 
ROS scavenging62 
 
yes 
 
MnTBAP 
 
Superoxide and H2O2 scavenging 63 
 
yes 
 
N-acetyl-cysteine 
 
ROS scavenging 64 
 
yes 
 
zVAD-FMK 
 
Broad-spectrum caspase inhibitor 59 
 
no 
 
n/a: not amenable to assessment due to toxic effects 
 
 
GD
FT
OR
GD
GD
GD G
D
GD
PrPSc
Normal/untreated
PrPC + PrPSc 
 PrPC + POM1 PrPC 
NOX2, calpains Neurotoxicity
POM1
POM2
 PrPC + POM1+ POM2 ∆OR + POM1
PrP(OR)n
toxicity prevented by FT ligands
(no steric hindrance)
toxicity prevented by OR deletion
spontaneous toxicity through 
supernumerary OR (hypothetical)
neurotoxicity in prion infections
(hypothetical)
Supplementary Figure 1. Models of PrP-mediated toxicity. a, The cellular prion protein PrP  C consists of a long 
flexible tail (FT) and a globular domain (GD) tethered to the membrane (blue) via a GPI anchor (green). GD ligands 
(holoantibodies, F(ab) fragments, or scFv minibodies) trigger neuronal loss, perhaps by altering the conformation of 
the FT relative to the membrane or to other molecules. b, Toxicity was abolished  by pretreatment with FT ligands that 
engaged the octapeptide repeats (OR), or by deleting the OR.  c, Supernumerary OR are associated with hereditary 
Creutzfeldt-Jakob disease and may plausibly also exert neurotoxicity through the FT. Bona fide prion infections may 
also conceivably utilize the same mechanism, as hypothesized in the right panel.
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Supplementary Figure 2. F(ab)1 fragments and holo 
antibodies are innocuous to Prnpo/o COCS. a, b, COCS 
prepared from Prnpo/o mice were incubated with antibodies to 
the FT or to the GD at 67 nM for 21 days (#: 200 nM, 21 days) 
(a), or with POM-derived F(ab)1 fragments at 134 nM for 21 
days (b). No neuronal loss was identified by NeuN 
morphometry, indicating that neurodegeneration required the 
presence of PrPC. Color codes denote the PrPC epitopes 
recognized by the various antibodies, as designated in Fig. 1. ). 
For all experiments, data in bar charts are reported as average ± 
s.d, n=9. One way ANOVA with Dunnett’s post-test. 
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Supplementary Figure 3. COCS viability after pulsed exposure to POM1. a, Treatment scheme for time 
course analysis. Slices were treated with antibodies either continuously (upper panel) or during pulses as specified 
(lower panel). b, Pulsed treatment. COCS were exposed to POM1 (67 nM) for 24-72h, and subsequently 
transferred to antibody-free medium. COCS were then cultured for various time intervals, and analyzed by NeuN 
morphometry (blue) or for PI incorporation (red). Even if short POM1 pulses did not induce histologically 
conspicuous CGC loss (as seen after protracted treatment), a significant spike of PI incorporation was consistently 
seen at 3 dpe. Data are reported as average ± s.d, n=9. One way ANOVA with Dunnett’s post-test. ***P<0.001. c, 
Conspicuous PI incorporation (dark dots within negative of fluorescent images) in the cerebellar granular layer 
(CGL) of POM1-exposed tga20 COCS (3dpe). 
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Supplementary Figure 4. Neuronal expression of PrPc is required for antibody-induced neurodegeneration. 
a, POM1 or control pooled IgG (267 nM, 28dpe) were administered to COCS expressing PrPC selectively in 
neurons (NSE-PrP), to COCS whose CGCs were selectively depleted of PrPC (GABA-Aα6-CRE
+;loxPrP-tg37, 
termed PrPΔCGC), to littermate control GABA-Aα6-CRE
¯;loxPrP-tg37 (termed PrPCGC+), and to COCS expressing 
PrPC selectively in oligodendrocytes (MBP-PrP). NSE-PrP and PrPCGC+ COCS underwent POM1-induced neuro- 
degeneration, whereas no toxicity was detected in PrPΔCGC and MBP-PrP COCS as assessed by NeuN 
morphometry. One way ANOVA with Tukey’s post-test. ***P<0.001, n.s.>0.05. b, ELISA assays showing that 
prion protein expression in the deletion mutants PrPΔ94-110 and PrPΔ32-93 (violet), as well as in the tissue-specific 
transgenic mice  NSE-PrP and MBP-PrP (red), was similar to that of wt mice. Hence the lack of POM1 toxicity in 
MBP-PrP COCS was not due to low PrPC expression. Data are presented as mean ± s.d., n=3 cerebella, repeated 
in duplicates. c, Tga20 COCS expressing the Herpes simplex virus thymidine kinase (TK) under the CD11b 
promoter were treated for 14 days with ganciclovir (GCV), which ablates microglia without affecting neuronal 
viability39, and subsequently treated with POM1 (167 nM) for 21 days. NeuN morphometry showed no effect of 
microglia depletion (red bars) on POM1 toxicity. One way ANOVA with Tukey’s post-test. ***P<0.001, 
n.s.>0.05. d, Tga20 COCS were treated with IgG, POM1 or anti-NOGO-R antibody (67 nM). POM1, but not 
anti-NOGO-R, induced neurodegeneration, indicating that damage was not a generic consequence of binding 
GPI-linked proteins. One way ANOVA with Dunnett’s post-test. ***P<0.001, n.s.>0.05. ). For all experiments, 
data in bar charts are reported as average ± s.d, n=9.
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Supplementary Figure 5. Neuronal loss mediated by monovalent antibody fragments. a, Purity of antibody 
preparations, as assessed by Coomassie blue-stained gels. Antibody fragments were obtained through enzymatic 
digestion of holoantibody and isolated by size-exclusion chromatography. Samples containing either pure F(ab)1 
or pure F(ab)2 fragments were pooled and used for experiments. b, Pools of F(ab)1 fragments were re-analyzed by 
size-exclusion chromatography after completion of the COCS exposure experiments. The elution profiles of F(ab)1 
fragments confirmed that the F(ab)1 fragment used for experiments did not contain any aggregated F(ab)1. mAU: 
milliabsorbance units. c, Time course of tga20 slices treated with IgG (67 nM here and henceforth, unless 
otherwise specified) or ScFvPOM1 (264 nM). Significant toxicity was present at ≥3 dpe. d, Tga20 slices were treated 
with IgG, scFvPOM1 (132 nM), or with ScFvPOM1 preincubated with rmPrP23-230  (370 or 3700 nM) for 7 days. The 
presence of rmPrP23-230  blocked the toxicity of scFvPOM1. e, Tga20 slices were exposed to various concentrations 
of scFvPOM1 for up to 7 days, and NeuN+ coverage within the CGC layer was assessed morphometrically. Toxicity 
was conspicuous at 264 nM with kinetics similar to POM1 (Fig. 2f).  For all experiments, data in bar charts are 
reported as average ± s.d, n=9. One way ANOVA with Dunnett’s post-test. ***P<0.001.
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Supplementary Figure 6. Neurotoxicity is independent of complement fixation, and active complement factors are absent 
from the culture medium. a, The relative lytic activities of anti-PrP antibodies3 (IgG1) and of the complement-activating 
antibody 34-3C (positive control, IgG2a) were assessed by pre-incubating Prnp
o/o (white bars) or tga20 (black bars) mouse 
erythrocytes with the respective antibodies. Erythrocytes were then washed and exposed to human serum. Ordinate: dilution of 
serum mediating 30% lysis of erythrocytes ± s.d., n=3. Antibody 34-3C was lytic to both tga20 and Prnpo/o erythrocytes. The 
highest PrPC-specific lytic activity was found for POM2, and no lysis was observed with IgG, POM3 or POM19. Hence 
neurotoxicity does not correlate with complement-mediated lytic activity and is unlikely to be caused by the latter. b, Tga20 
erythrocytes were coated with antibody 34-3C, washed, and incubated with various dilutions of normal human serum (black bars), 
horse serum (blue bars), or heat-inactivated horse serum (hiHorse, red bars). White bars represent erythrocytes left untreated or 
incubated with 34-3C (negative control) or deionized water (positive control) in the absence of serum. Ordinate: hemoglobin 
released from lysed erythrocytes was measured spectrophotometrically (Absorbance at 414nm) ± s.d., n=4. The 
complement-fixing antibody 34-3C was highly lytic in human serum, yet failed to lyse erythrocytes in the medium used for 
culturing COCS, indicating that active complement factors were absent from the culture medium. 
Supplementary Figure 7. X-ray analysis of the complex rmPrP120-230 and F(ab)1POM1. Secondary structure 
and surface representation of the protein complex between the GD of rmPrP120- 230  and F(ab)1POM1. The heavy 
chain and the light chain of F(ab)1POM1 are represented in salmon and cyan, respectively, whereas rmPrP120-230 is 
shown in green. A close-up view of the intermolecular contacts between F(ab)1POM1 and rmPrP120-230 is presented 
below. Interacting residues are displayed in stick representation and hydrogen bonding interactions are shown in 
black dashed lines.
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Supplementary Figure 8. NMR analysis of scFvPOM1 binding to rmPrP23-230. Superposition of 2D 
[1H-15N]-transverse relaxation optimized spectroscopy (TROSY)-spectra of [2H,15N]-labeled rmPrP23-230 in the 
absence (grey spectrum) and presence (red spectrum) of stoichiometric amounts of unlabeled scFvPOM1. For 
simplicity, only isolated cross peaks are marked. Black labels represent residues of rmPrP23-230 that are in direct or 
close contact with scFvPOM1. Blue labels indicate the FT. The overlay of the spectra shows the close resemblance 
of cross peaks to the residues of the FT, indicating that the scFvPOM1 does not significantly affect the structure of 
the FT. As expected, strong chemical shift perturbations are observed for residues that directly interact or in close 
contact with scFvPOM1. Minor chemical shift perturbations are also visible for some β1/β2 residues (e.g. G130 and 
V160).
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Supplementary Figure 9. The FT transduces GD ligand toxicity. a, Domains of 
PrPC and deletion mutants used in Figure 3a, Figure 4e and Figure 4f. SP, signal 
peptide; OR, Octapeptide repeats; CC1-CC2, charged cluster 1 and 2; HC, 
hydrophobic core; α1-3, αhelices 1-3; GPI, glycosyl phosphatidyl inositol anchor. 
b, NeuN morphometry of COCS treated with various POM antibodies (167-267 
nM, 28 dpe). Wt COCS (white) experienced toxicity after exposure to POM4, 
POM8, or POM19, whereas PrPΔ32-93 (red) and Prnp
o/o COCS (black) were resistant 
to the same antibodies. Data are reported as average ± s.d, n=9. One way ANOVA 
with Tukey’s post-test. ***P<0.001, n.s.>0.05. c, PrPC expression levels. 
PNGase-treated cerebellar homogenates of 10 day-old mice were probed with 
antibodies to the GD (POM1) and the FT (POM2). While tga20 pups expressed the 
highest levels of PrPC, PrPΔ94-110 and PrPΔ32-93 pups expressed PrP at levels similar 
to, or higher than, wild type (wt). FL; full-length PrP; C1 and C2: carboxy 
proximal PrP cleavage fragments (111-230 and 93-230, respectively). As 
expected, POM2 did not recognize PrP∆32-93 as well as the C1 and C2 cleavage 
fragments, since it is directed to the octapeptide repeats. d, matrix indicating which 
antibody pairs exhibit competition or steric hindrance (blue) based on SPR 
competition experiments published elsewhere3. These results are reproduced here 
for convenience and demonstrate that POM1 does not compete with POM5 for a 
common binding site. e, Tga20 COCS were treated with POM1 (67 nM) in 
presence or absence of another GD antibody, POM5 (67 nM) for 10 days. POM5 
was not toxic by itself, and yet – in contrast to the antibodies directed against the 
FT – it did not prevent POM1 toxicity. Data are reported as average ± s.d, n=9. One 
way ANOVA with Dunnett’s post-test, n.s.>0.05.
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Supplementary Figure 10. Ultrastructural characterization of toxicity in COCS treated with IgG or POM1 
(67 nM). a-b, After 7 days of IgG treatment, COCS exhibited healthy CGL morphology (a) (magnification: see 
scale bar), whereas after POM1 treatment, most of CGCs showed irregular and condensed nuclear chromatin (b). 
c, Number of cells displaying normal, apoptotic, or necrotic nuclear morphology (average cells/field at x300 
magnification ± s.d., at least 10 fields were analyzed) after treatment with POM1 or control IgG for various time 
periods (3-10 days). d, POM1-treated slices at 7 dpe showed nuclear chromatin condensation. 
Ascorbate [ M]:  -        -μ 20   100   500  2500
POM1
Ig
G
b
+I
so
as
co
rb
at
e
)
%( 
Nue
N
***
***
**
+A
sc
or
ba
te
+z
VA
D
+C
al
pe
pt
in
+N
A
C
+1
40
0W
+M
nT
B
AP
+1
40
0W
+M
nT
B
AP
50
100
10 10
0
10
00
0
0.5
1.0
1.5
2.0
0 µM Asc
50 µM Asc
500 µM Asc
5000 µM Asc
POM1 [pg/ml]
Ab
so
rb
an
ce
c
50
100
150
a
)
%( 
Nue
N
0 n
o 
to
ol
 c
om
po
un
d
no
 to
ol
 c
om
po
un
d
no
 to
ol
 c
om
po
un
d
no
 to
ol
 c
om
po
un
d
Supplementary Figure 11. Treatment with various tool compounds did not affect viability and antibody 
binding properties. a, COCS prepared from tga20 mice were treated with pooled IgG at 67 nM for 10-14 days in 
the presence of the compounds listed in the figure. Dotted lines delimit biologically distinct experiments, 
performed on different sets of COCS along with controls. None of the compounds tested affected the viability of 
COCS, as assessed by NeuN morphometry. b, COCS prepared from tga20 mice were treated with various 
concentrations of ascorbate and exposed to POM1 (67 nM) for 10 days. Ascorbate was protective at concentrations 
of  >100 µM, but not at 20 µM. For all experiments data in bar charts are reported as average ± s.d, n=9. One way 
ANOVA with Dunnett’s post-test. ***P<0.001, **P<0.01. c, Aliquots of POM1 were incubated with various 
concentrations of ascorbate (0-5000 µM) for 48h at 37 °C, and subsequently used for detecting rmPrP23-230 
immobilized on microtiter plates. POM1 was visualized with HRP-conjugated anti-mouse IgG antibody and 
chemiluminescence. The presence of ascorbate did not exert any influence on the binding capacity of POM1. Each 
data point represents mean ± s.d, n=3.
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Supplementary Figure 12. Temporal evolution of lesions in mouse cerebella injected with POM1. a, 
Schematic representation of the murine cerebellum. Crosshairs (red) denote the site of injection. b, Representative 
MRI scans before injection (prescan) and at 4h, 24h, and 72h after POM1 injection in tga20 and Prnpo/o mice. In 
tga20 mice, incipient edema was recognizable as marginal hypointensity already at 4h. After 24h and 72h, 
hypointense lesions were fully developed and involved several folia. In contrast, POM1 injected Prnpo/o mice 
showed only a small hypointensity in the area of the needle tract.
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Supplementary Figure 13. Representative hematoxylin-eosin sections from POM1-injected tga20 and 
Prnpo/o mouse cerebella. a, Chromatin condensation in cerebellar granular cells (black arrow head) was seen as 
early as 5h post-injection. b, Progression to edema and macrophage infiltration (black arrow) was seen after 24h. 
c, One week post injection, prominent loss of granular cell neurons and brisk Bergman glia proliferation (black 
arrow) were evident. The differential survival of Purkinje neurons (white arrowheads) is consistent with the lack 
of PrPC expression in Purkinje neurons of tga20 mice. 
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Supplementary Figure 14. Stereotactic injection of POM1, D13 and IgG (6ug) into tga20 hippocampi.  a, 
Schematic representation of the murine hippocampus. Crosshairs (red) denote the site of injection. CA1-3: Cornu 
ammonis sectors 1-3. DG: Dentate gyrus. b, Volumetric assessment of the size of CA3 and DG [mm3] ipsilaterally (il) 
and contralaterally (cl) to antibody injection in tga20 mice (48h post-injection). Both POM1 and D13 led to a 
reduction in CA3 volume ipsilaterally.  Data are presented as mean ± s.d., n=4, One-way ANOVA with Dunnett’s 
post-test, ***P<0.001, *P<0.1.). c, MEMRI (left panels) showing loss of the CA2-3 contour and appearance of a 
hypointense lesion ipsilaterally (il) to the site of POM1 and D13 injection, whereas the contralateral site (cl) did not 
show lesions after IgG injection. Histological analysis 48h post injection (right panels) showed loss of NeuN+ neurons 
in the dentate gyrus and in the CA3 sector after POM1 and D13 injection. 
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Supplementary Figure 15. a, b, Representative H&E histology of mice pretreated with acetylated hydroxyl tyrosol 
and injected with scFvPOM1. Hematoxylin-eosin stained sections of mouse cerebella. Whereas vehicle-treated mice 
developed large areas of cell death around the site of injection (yellow dashed line), only small lesions were visible in 
treated mice in the immediate vicinity of the needle tract (yellow asterisk). Rectangles indicate the position of the high 
magnification pictures shown in the right-side panels.   
